In the Claims

1.- 42. (Canceled)

43. (Currently Amended) A pharmaceutical composition comprising:

a therapeutically effective amount of an antigen presenting cell pulsed with an inactivated non-recombinant human immunodeficiency virus (HIV); and

a pharmaceutically acceptable carrier;

wherein the inactivated human immunodeficiency virus is chemically inactivated by 2,2'-dithiopyridine, and wherein the composition expands *in vivo* expression of virus-specific CD8+ T cells, and said virus-specific CD8+ cells kill HIV-infected cells.

44. (Previously presented) The pharmaceutical composition of Claim 43, wherein said inactivated human immunodeficiency virus is an inactivated autologous human immunodeficiency virus.

45. (Previously presented) The pharmaceutical composition of Claim 43, wherein said antigen-presenting cell is a dendritic cell.

46. (Previously presented) The pharmaceutical composition of Claim 45, wherein said dendritic cell is an autologous dendritic cell.

47. (Previously presented) The pharmaceutical composition of Claim 45, wherein the dendritic cell is a monocyte-derived dendritic cell.

48.-50. (Cancelled)

51. (Currently Amended) The pharmaceutical composition of Claim ~~48~~ 43, wherein the inactivated human immunodeficiency virus is an inactivated autologous human immunodeficiency virus.

52. (New) The pharmaceutical composition of claim 43, further comprising an adjuvant for optimizing the virus-specific CTL response.

53. (New) The pharmaceutical composition of claim 52, wherein said adjuvant is a protease inhibitor.

54. (New) The pharmaceutical composition of claim 53, wherein said protease inhibitor is indinavir.

55. (New) The pharmaceutical composition of claim 54, wherein said composition comprises non-antiviral concentration of indinavir.

56. (New) The pharmaceutical composition of claim 55, comprising a concentration of indinavir of about 10 nM.